Global Auto-Injector Market Report 2021-2026: Rising Prevalence of Targeted Therapies, Rising Incidence of Anaphylaxis, and Rising Number of Regulatory Approvals –

DUBLIN – (COMMERCIAL THREAD)–The “Auto-injectors: global markets 2021-2026” the report was added to offer.

The global auto-injector market is expected to grow from $ 41.5 billion in 2021 to $ 85.2 billion by 2026, at a compound annual growth rate (CAGR) of 15.5% for the period 2021- 2026.

  • The North American auto-injector market is expected to grow from $ 15.1 billion in 2021 to $ 28.4 billion by 2026, at a CAGR of 13.4% for the period 2021-2026.

  • The Asia-Pacific auto-injector market is expected to grow from $ 10.2 billion in 2021 to $ 22.6 billion by 2026, at a CAGR of 17.2% for the period 2021-2026.

The increasing prevalence of targeted therapies, the increasing incidence of anaphylaxis, and the growing number of regulatory approvals are factors responsible for this market growth.

Auto-injectors are pen-like devices used to deliver a fixed dose of a drug to a patient and are intended for self-administration. Auto-injectors are gradually becoming the benchmark in the treatment of indications such as anaphylaxis, multiple sclerosis and rheumatoid arthritis. Most auto-injectors are spring-loaded and the self-injection procedure is relatively straightforward.

These instruments can help prevent needle stick injuries and reduce needle phobia in patients. Auto-injector manufacturers are focusing on user-centered approaches to improve ease of use and overcome anxiety associated with self-administration of intramuscular injections.

Auto-injectors are expected to present major opportunities to investors due to the strong demand for biologics development. Since the procedure does not require a visit to a hospital or clinic, it reduces reliance on healthcare professionals. The increasing adoption of auto-injectors due to advantages such as increased safety, accuracy, and minimal discomfort is expected to fuel the market revenue growth during the forecast period.

The report also includes market projections to 2026 and rankings of the major market players. The report segments the auto-injector market on the basis of product type, route of administration, therapy, end-user, and geography or region.

The report includes

  • In depth review of the global auto-injector market in the medical device industry

  • Global market trend analyzes, with data from 2019 to 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) to 2026

  • Global Auto-Injectors Market Size Assessment and Forecast in Dollar Value and Analysis of Corresponding Market Share by Product Type, Route of Administration, Therapy, End User, and Region

  • Discussion of key market dynamics (DRO), technological advancements, regulatory scenario, price analysis and competitive environment of supplier companies

  • Country specific data and market value analysis for United States, Canada, United Kingdom, France, Germany, Italy, Spain, Japan, China and India

  • Overview of recent industry strategies, major M&A transactions, company competitive landscape and value share analysis of major players operating in the global Auto-Injectors Market

  • Highlights of Auto-Injectors Market Potential, Opportunities and Gaps Estimating Current and Future Demand, and Impact of COVID-19 on the Progress of this Market

  • Discussion on the competitive intensity among major market players, their global rankings, and recent developments in the Auto-Injectors market

  • Company Profile Descriptions of Major Self-Injection Device Manufacturers and Suppliers including AbbVie Inc., Amgen Inc., Becton, Dickinson and Co., Eli Lilly, GlaxoSmithKline PLC, Johnson & Johnson, Merck KGaA, and Teva Pharmaceutical

Main topics covered:

Chapter 1 Introduction

  • Study goals and objectives

  • Reasons for doing this study

  • Scope of the report

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • introduction

  • Evolution of market

Chapter 4 Impact of the COVID-19 pandemic

  • Impact of COVID-19 on the markets

  • Changing trends in the consumption of health-related products

Chapter 5 Market Dynamics

  • Overview

  • Increased incidence of anaphylaxis

  • Growing prevalence of targeted therapies

  • Market constraints

  • Presence of other routes of drug administration

  • Strict regulation scenario

Chapter 6 Market Breakdown by Product Type

  • Auto-Injectors Market by Product Type

  • Disposable auto-injectors

  • Market size and forecast

  • Reusable auto-injectors

  • Market size and forecast

Chapter 7 Market breakdown by administration

  • Auto-Injector Market by Route of Administration

  • Intramuscular

  • Market size and forecast

  • Subcutaneous

  • Market size and forecast

Chapter 8 Market Split by Therapy

  • Anaphylaxis

  • Market size and forecast

  • Rheumatoid arthritis

  • Multiple sclerosis

  • Diabetes

Chapter 9 Market Breakdown by End User

  • Home care settings

  • Market size and forecast

  • Hospitals and clinics

  • Ambulatory care settings

Chapter 10 Market Breakdown by Region

  • North America

  • United States

  • Canada

  • Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The rest of europe

  • Asia Pacific

  • China

  • Japan

  • India

  • Rest of Asia-Pacific

  • Latin America

  • Middle East and Africa

Chapter 11 Regulatory Scenarios

  • Definition and classification of medical devices

  • Regulations in the United States

  • Code of Federal Regulations

  • Electronic Code of Federal Regulations

  • 510 (k) Pre-Marketing Notice Marketing Authorization

  • 510 (k) Exempt devices

  • Pre-market approval

  • European regulations

  • Regulations in North American countries

  • American regulations

  • Canadian regulations

  • Regulations in Latin America

  • Regulation in Asia-Pacific

  • Future regulatory trends

Chapter 12 Competitive Landscape

  • Overview

  • Company rankings

Chapter 13 Company Profiles

  • Abbvie inc.

  • Amgen Inc.

  • Antares Pharma inc.

  • Becton, Dickinson et Cie.

  • Eli Lilly et Cie.

  • GlaxoSmithKline Plc

  • Johnson & johnson

  • Merck Kgaa

  • SHL Medical Ag

  • Teva Pharmaceutical Industries Ltd.

  • Ypsomed

For more information on this report, visit

Comments are closed.